Skyrizi vs Taltz
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Skyrizi | US Taltz | |
|---|---|---|
| Generic name | risankizumab | ixekizumab |
| Drug class | IL-23 Inhibitor (Biologic) | IL-17A Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Eli Lilly |
| Year approved | 2019 | 2016 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $480M | $190M |
| Common side effects | Respiratory infections, Headache, Fatigue, Injection site reactions | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count |
Frequently asked questions
Is Skyrizi or Taltz better?
Neither is universally "better." Skyrizi (risankizumab) and Taltz (ixekizumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Skyrizi and Taltz?
Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie, while Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.